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Objective: To explore the structure and content of a
non-random sample of clinical study reports (CSRs) to
guide clinicians and systematic reviewers.
Search strategy: We searched public sources and
lodged Freedom of Information requests for previously
confidential CSRs primarily written by the industry for
regulators.
Selection criteria: CSRs reporting sufficient
information for extraction (‘adequate’).
Primary outcome measures: Presence and length
of essential elements of trial design and reporting and
compression factor (ratio of page length for CSRs
compared to its published counterpart in a scientific
journal).
Data extraction: Data were extracted on standard
forms and crosschecked for accuracy.
Results: We assembled a population of 78 CSRs
(covering 90 randomised controlled trials; 144 610
pages total) dated 1991–2011 of 14 pharmaceuticals.
Report synopses had a median length of 5 pages,
efficacy evaluation 13.5 pages, safety evaluation
17 pages, attached tables 337 pages, trial protocol
62 pages, statistical analysis plan 15 pages and
individual efficacy and safety listings had a median
length of 447 and 109.5 pages, respectively. While
16 (21%) of CSRs contained completed case report
forms, these were accessible to us in only one case
(765 pages representing 16 individuals). Compression
factors ranged between 1 and 8805.
Conclusions: Clinical study reports represent a
hitherto mostly hidden and untapped source of detailed
and exhaustive data on each trial. They should be
consulted by independent parties interested in a
detailed record of a clinical trial, and should form the
basic unit for evidence synthesis as their use is likely
to minimise the problem of reporting bias. We cannot
say whether our sample is representative and whether
our conclusions are generalisable to an undefined and
undefinable population of CSRs.
INTRODUCTION
Systematic reviews are thought to provide
one of the most robust ways to evaluate
the effects of healthcare interventions. But
the robustness of findings clearly rests upon
reviewers having sufficient access to clinical
trial information to critically evaluate and
reproduce the original research. Research on
reporting bias over the last decades has
shown that trusting the published literature
at face value, even peer-reviewed publica-
tions, can be fraught with difficulty—a
problem that spans drug classes.1–12
Following the decision by the European
regulator, the European Medicines Agency
(EMA) on 30 November 2010, to make avail-
able a broad spectrum of documents related to
medicinal products for human and veterinary
use,13 14 attention has focused on one particu-
lar type of regulatory document—clinical study
reports (CSRs).15–18 CSRs are usually written
ARTICLE SUMMARY
Article focus
▪ What are clinical study reports (CSRs)? What do
they contain and how long are they?
▪ Can CSRs help address reporting biases asso-
ciated with the published literature, and improve
the quality of evidence synthesis?
Key messages
▪ CSRs represent a hitherto hidden and untapped
source of detailed randomised controlled trial
data (mean page length: 1854 pages), increas-
ingly becoming publicly available, and should
form the basic unit for evidence synthesis to
minimise the problem of reporting bias.
▪ CSRs show that numerous individuals make
important technical contributions to the design,
conduct and reporting of each trial, but journal
publications often fail to record these details,
resulting in a loss in individual responsibility for
what is reported.
▪ The ICH E3 guideline to which most CSRs
conform was published in 1995, and needs
updating.
Strengths and limitations of this study
▪ We cannot say whether our sample is represen-
tative and whether our conclusions are generalis-
able to an undefined and undefinable population
of CSRs.
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for regulators following guidelines developed by the
industry regulatory collaborative effort ‘International
Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use’
(ICH). The ICH guidelines ‘structure and content of
clinical study reports’19 (see online supplementary appen-
dix 1) are known by the document code ‘E3’. They were
formalised in 1995 ‘to assist sponsors in the development
of a report that is complete, free from ambiguity, well orga-
nised and easy [for regulators] to review’.19 E3 has not
been edited or changed since 1995.
CSRs are but one category of information that is trans-
mitted from study sponsors to regulators (figure 1), but
are important as they contain substantially more informa-
tion and detail on the intervention being tested than pub-
lished versions of the same trial. The wealth of information
may be sought with increasing frequency by researchers
appraising single trials, entire trial programmes, or by
those synthesising evidence.17 20 We are aware of two
recent examples of systematic reviews of the effects of phar-
maceuticals carried out using CSRs and other regulatory
material.12 21 One group also concluded that journal publi-
cations insufficiently report clinical trials.22
Despite CSRs’ potential importance little is known
about their structure and content outside of those indivi-
duals with direct involvement in regulatory processes.
This knowledge gap may hinder development of
methods for fair and reliable appraisal of CSRs and
their use in evidence synthesis. We are not aware of any
instruments specifically designed for appraising CSRs.
Lack of visibility may also hinder understanding of
the complexity of the organisation and the reporting of
clinical trials.
We carried out an exploratory review to describe the
structure and content of a non-random sample of CSRs.
By describing the contents of CSRs, this research seeks
to transform CSRs from an obscure document only
known to regulators and industry into a more widely
known and accessible document. Our long-term inten-
tion is to improve the credibility of research synthesis by
facilitating a move from the level of detail found in
journal articles to the level of detail found in regulatory
documents, thus guiding clinicians and other decision
makers at all levels.
METHODS
We obtained CSRs from public sources, as follows:
1. Requesting from EMA, under its Freedom of
Information (FOI) policy, CSRs for manufacturer-
sponsored trials of the 10 best-selling prescription-
bound products in the USA in 2010.23
2. Reusing CSRs from our own previous research (osel-
tamivir and zanamivir).12
3. Downloading CSRs openly available on the Internet.
Search terms were not predefined, but sites searched
Figure 1 Types of clinical trial
data typically held within and
transferred between three realms:
trial sponsor, regulatory and
public.
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included Google (http://www.google.com), the Drug
Industry Document Archive (http://dida.library.ucsf.
edu/) and Institut für Qualität und Wirtschaftlichkeit
im Gesundheitswesen (Institute for Quality and
Efficiency in Healthcare) (IQWiG)’s library of rebox-
etine studies (https://www.iqwig.de/information-
on-studies-of-reboxetine.980.en.html).
4. Corresponding with one researcher who obtained
CSRs through an FOI request to Food and Drug
Administration (FDA) (epoetin alfa).
5. Requesting manufacturers fill any gaps in the com-
pleteness of reports that we believe are legally
required to be publicly available (paroxetine).
To create as broad a database as possible, we did not
apply restrictions in drug type or family or sponsor. We did
not submit requests under the Freedom of Information
Act to the FDA, because such requests can take years to be
fulfilled and—if fulfilled—may be heavily redacted.24
We did not draw a random sample of CSRs as there is
no known sampling frame. No one knows how many
reports have been written by intervention category as
there is no central register of CSRs. Through familiarity
with CSRs for oseltamivir and zanamivir, which were
included in one of our Cochrane reviews,12 we devel-
oped and piloted a data extraction sheet designed to
capture the salient characteristics of CSRs. We created a
list of around 40 potential sections we expected to find,
generated directly from elements specified in E3. For
each element in the list, we checked whether the
obtained CSRs included that section (confirmed either
by direct identification of the section or an indication
the section existed based on the CSRs’ table of con-
tents), whether we had access to it and its page length.
Because of previous difficulties we had accessing CSRs
appendices, we also recorded whether sections were
listed as appendices or not. The page length was calcu-
lated either by directly counting the pages or by estimat-
ing their size from the table of contents of each report,
and was used as a crude proxy for the level of detail
available. The page lengths were rounded up to the next
integer, and were summarised by reporting medians and
ranges. We also included questions relating to trial regis-
tration and authorship. Our (blank) data extraction
sheet is in online supplementary appendix 2.
All variables from CSRs were first extracted in single.
We subsequently audited each other’s extractions, check-
ing the accurateness of the information. We chose to
present elements analogous with those that typically
appear in trials reported in scientific journals including
the study synopsis (a brief summary of the study), the
study protocol (written prospectively, describing the study
methods), efficacy and safety evaluations (a narrative
summary of the efficacy and safety results of the study,
including tables and figures), as well as attached tables.
We also included elements rarely found in journal publi-
cations: sample (blank) and completed case report forms
(CRFs are paper or electronic forms designed to capture
prespecified efficacy and safety related information
for each study participant), the statistical analysis plan (a
prospectively written narrative and/or statistical code
indicating how trial data will be analysed) and individual
participant efficacy and safety listings. The corresponding
E3 section numbers are listed in table 2. Disagreements
were resolved by discussion.
Our uncorrected (original) and corrected extraction
sheets as well as audit records are available upon request
from the corresponding author.
We calculated a compression factor for published
trials which we defined as the ratio of CSR page length
compared to the page length of the same trial as pub-
lished in scientific journals. The objective of this metric
was to convey a rough sense of how much information
present in CSRs may be condensed (‘compressed’) in
short journal publications, in consideration of CSRs’ far
greater length and level of detail. The size (page
length) reflects the level of detail as well as the presence
of many elements such as protocols and their amend-
ments, randomisation lists, statistical analysis plans, certi-
ficates of analysis and extra data on subpopulations. We
have demonstrated12 that these elements are essential
for understanding and appraising a trial. The compres-
sion factor is a crude measure of how much is com-
pressed or simply left out of each publication which will
affect the reliability of the appraisal and interpretation
of trials. Trial publications were searched for in multiple
sources—clinical trial registers, published systematic
reviews and correspondence with sponsors. Because in
most cases we could not access all parts of all CSRs (and
therefore do not know their complete page length), we
calculated ‘conservative’ compression factors as well as
‘realistic’ compression factors. ‘Conservative’ compres-
sion factors were calculated on a trial by trial basis using
the total number of pages in CSRs available to us
divided by the length of journal reports for that same
trial, whereas ‘realistic’ compression factors were based
on the true total page length of the CSRs.
RESULTS
We identified 84 documents believed to be CSRs for 14
compounds. These covered therapeutic and biological
interventions including antipsychotics, antidepressants,
antivirals, natural antiarthritics, anti-inflammatory
agents, pandemic influenza vaccines, statins, erythro-
poietins and antiplatelet compounds. We included
English-language summaries of two Japanese oseltamivir
studies ( JV15823 and JV15824) as they had been pre-
sented to EMA in this form. We excluded documents
which were sections of CSRs that nonetheless contained
insufficient information to understand the overall
content of the CSRs (olanzapine F1D-LC-HGAV,
F1D-MC-HGAJ and F1D-MC-HGAO) and three docu-
ments which we had originally classified as CSRs but
were not (reboxetine 14, 22 and 37). This left us with 78
CSRs (144 610 pages) (figure 2). The median pages
obtained per CSR was 644 (range 9–15 440). Only 4 of
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78 CSRs (reboxetine 8, 16, 17 and 91) were written
prior to 30 November 1995 when ICH E3 was approved.
Table 1 summarises the pharmaceutical, manufacturer,
date and provenance of the CSRs in our review. EMA
reported not holding studies for esomeprazole magne-
sium (Nexium), Advair Diskus, quetiapine fumarate
(Seroquel), montelukast sodium (Singulair), epoetin
alfa (Epogen) and simvastatin.
All of the 78 included CSRs contained a synopsis
(median page length 5 pages). The efficacy evaluation
was identifiable and directly accessible in 76 (97%;
median length 13.5 pages) and safety in 77 (99%;
median length 17 pages). The attached tables were like-
wise present in 63 (81%) CSRs, with a median of 337
pages long (range 1–3665). Seventy-three CSRs (94%)
reported including the study protocol. In the 40 proto-
cols we could access, the median page length was 62. We
found blank CRFs included in 68 (87%) CSRs. Of the 33
blank CRFs we could directly access, the median length
was 133 pages (range 14–981). For completed CRFs, 16
(21%) reports made direct mention of a section on com-
pleted CRFs, but we had access to completed CRFs in
only 1 case (Arthronat; length 765 pages).
Fifty-five (71%) of 78 included CSRs included a statis-
tical analysis plan in some form. Of those for which we
could directly access the content (n=37), the median page
length was 15 (range 3–85). Individual efficacy and safety
listings were included in 53 (69%) and 62 (81%) CSRs,
respectively. The median page length was 447 (range 15–
21 698) for efficacy and 109.5 (range 2–10 954) for safety.
A summary is presented in table 2.
All trial reports in our review were sponsored by the
pharmaceutical industry.
Median conservative compression factors ranged
between 1 and 1221. The realistic compression factors
calculated for the Arthronat, paroxetine and
Clopidogrel versus Aspirin In Patients at Risk of
Ischaemic Events (CAPRIE) trials were 379, 1021 and
8805, respectively (table 3).
DISCUSSION
We collected and described a sizeable number of CSRs
written in the last two decades. All CSRs contained a table
of contents (as specified in E3 section 3); this, together
with optical character recognition (to enable searching the
full text of the scanned documents) and the occasional
need to combine multiple files to create a single docu-
ment, substantially improved the ease of navigating CSRs.
Despite the size of our non-random sample, it is
unclear whether our conclusions are generalisable to all
other CSRs. This is because we have extremely limited
knowledge about the total population of CSRs in regula-
tors’ and sponsors’ possession. Nevertheless, within our
sample spanning different manufacturers, therapeutic
classes and times, we found that the structure of CSRs
was, within different house styles of presentation, strik-
ingly similar, probably owing to the guidance by ICH
E3.25 This suggests that the structure and content of
other CSRs is likely to be similar.
Figure 2 Study flow.
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Table 1 Pharmaceutical, trials, producers, dates and sources of CSRs in the review
Pharmaceutical and
number (n) of assessed
trial documents Trial IDs Manufacturer
Date of
CSRs Provenance in our study
Aripiprazole (Abilify) n=1 CN1368135 Bristol-Myers
Squibb
2007 Freedom of Information request to the EMA
Arthronat n=1 MA-CT-10–002 Rowtasha 2011 Manufacturer website http://arthronat.com/clinical-study.php
Atorvastatin (Lipitor) n=1 981–080 Pfizer 1999 Freedom of Information request to the EMA




1997–2007 Freedom of Information request to the EMA
Epoetin alfa (Epogen) n=1 930 107 Amgen 1996 Freedom of Information request to the FDA
H5N1 influenza vaccine
n=1
H5N1–008, H5N1–011 EXT 008 GSK 2006 Freedom of Information request to the EMA
H5N1 influenza vaccines
n=2
V87P1, V87P6 Novartis 2008–2009 Freedom of Information request to the EMA
Olanzapine (Zyprexa) n=3 F1D-LC-HGAV*, F1D-MC-HGAO*,
F1D-MC-HGAJ*
Eli Lilly 1995† Litigation http://www.furiousseasons.com/zyprexadocs.html
Oseltamivir (Tamiflu) n=19 JV15823, JV15824, M76001, NP15757,
NV16871, WP16263, WV15670, WV15671,
WV15673, WV15697, WV15707, WV15708,
WV15730, WV15758, WV15759, WV15871,
WV15799, WV15812, WV15872, WV15819,
WV15876, WV15978, WV15825, WV16193




329, 377, 453, 511, 676, 701, 704, 715, 716 GSK 1998–2002 Litigation (2004 legal settlement mandated release of clinical
study reports on manufacturer’s website of 9 studies on
paediatric and adolescent patients) http://www.gsk.com/
media/paroxetine.htm





8, 9, 13, 14*, 15, 16, 17, 22*, 32, 32a, 34,
35, 37*, 43, 45, 46, 47, 49, 50, 52, 71, 83,
91, 96
Pfizer 1991–2009 Health technology assessment website (The German IQWiG
obtained CSRs as part of its health technology assessment
work) https://www.iqwig.de/
information-on-studies-of-reboxetine.980.en.html
Rofecoxib (Vioxx) n=1 78 Merck 2003 Litigation http://dida.library.ucsf.edu/
Zanamivir (Relenza) n=9 NAI30009, NAI300010, NAIA2005,
NAIA3002, NAIA3005, NAIB2005,
NAIB2007, NAIB3001, NAIB3002
GSK 1998–1999 Documents obtained as part of previous Cochrane review12
*Subsequently excluded because of insufficient documentation.
†H1D-MC-HGAO clinical study report date unknown.
CSRs, clinical study reports; EMA, European Medicines Agency; FDA, Food and Drug Administration; GSK, GlaxoSmithKline; IQWiG, Institute for Quality and Efficiency in Healthcare;







































The future basic currency of research synthesis?
The median length of 644 pages for reports in this
study, as well as CSRs’ routine inclusion of trials’ proto-
col, statistical analysis plans and blank case report forms,
strongly suggests that CSRs are the most detailed and
complete, integrated form of reporting of the design,
conduct and results of clinical trials. In a study that dir-
ectly compared the adequacy of reporting between
journal articles and CSRs, the authors found that com-
plete information regarding greater than 40% of
methods items were only available in CSRs.22 The level
of detail found in CSRs thus far surpass the level of
detail available in journal publications, and as such they
are prime candidates for the next basic currency of evi-
dence synthesis and appraisal of a trial. Given the EMA’s
new policy of making such documents publicly available,
access to these documents is now relatively straightfor-
ward.26 However, including CSRs in systematic reviews is
labor-intensive, given their size and complexity.12
Accessing complete CSRs
Although CSRs may trump other forms of trial reporting
in the public domain (such as conference abstracts or
journal publications), serious limitations remain. Despite
obtaining 144 610 pages for 78 CSRs, in almost all
instances, we lacked complete access to the CSRs’
numerous appendices. Even for the sole complete CSR
we obtained (Arthronat MA-CT-10–002), case report
forms were provided for only 20% of participants. The
Arthronat text does not provide a reason for this omis-
sion, but it reflects the vagueness of the relevant section
of the E3 guidance (16.3.2) which does not define
‘other CRFs submitted’. Also, we could only access the
original trial protocol in 40 (51%) of 78 CSRs obtained.
This is important because trial protocols, written prior
to patient enrollment in a trial, are an important way to
guard against reporting biases.27 28
We could obtain individual patient listings in only a
minority of cases despite confirming their inclusion in the
majority of CSRs (table 2). This may be a significant
limitation, as the E3 specifies that ‘the report with its
appendices should also provide enough individual patient
data, including the demographic and baseline data, and
details of analytical methods, to allow replication of the crit-
ical analyses.’19 Unavailability was possibly owing to the fact
that EMA allows manufacturers to submit CSRs omitting a
number of appendices including individual patient data
and case report forms (which EMA states should be avail-
able within 48 h, if requested).29 In the case of oseltamivir,
the primary drug analysed in a Cochrane review we con-
ducted,12 the manufacturer refused to share with us report
appendices not submitted to EMA,30 and EMA declined
requesting them on our behalf.
8
Although FDA likely pos-
sesses more complete CSRs and patient-level data, it histor-
ically has treated such data as trade secret and/or
confidential.31–33 EMA is therefore at present the only
Table 2 Key characteristics of the clinical study reports in the review








Synopsis (E3 section 2) 78 (100%) 78 5 (1–15)
Efficacy evaluation (E3 section 11) 76 (97%) 77 13.5 (2–132)
Safety evaluation (E3 section 12) 77 (99%) 58 17 (2–188)
Attached tables not in report text (E3 section 14) 63 (81%) 76 337 (1–3665)
Protocol (E3 section 16.1.1) 73 (94%) 41 62 (21–139)
Blank CRFs (E3 section 16.1.2) 68 (87%) 33 133 (14–981)
Statistical analysis plan (E3 section 16.1.9) 55 (71%) 37 15 (3–85)
Individual participant efficacy listings (E3 section 16.2.6) 53 (69%) 19 447 (15–21698)
Individual participant safety listings (E3 section 16.2.7) 62 (81%) 26 109.5 (2–10954)
Completed CRFs (E3 section 16.3.2) 16 (21%) 1 765
CRFs, case report forms; CSRs, clinical study reports; E3, ICH E3.










Clopidogrel 5 11 (4–19)
Epoetin alfa 1 41
Fluad 2 488 (367–609)
GSK H5N1 vaccine 1 19
Oseltamivir 12 195 (1–1221)
Quetiapine 2 578 (352–803)
Reboxetine 5 88 (9–245)




Paroxetine 9 1021 (50–5473)
A ratio of clinical study report page length to corresponding journal
publication page length.
*The Arthronat trial has not yet been published. Compression
factor calculation is based on the page length of a draft
manuscript ‘to be published soon,’ according to Arthronat.com.
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reliable source of obtaining CSRs. As such, despite
European regulators’ progressive stance—announcing that
‘clinical trial data should not be considered commercial
confidential information’34—the completeness gap is
unlikely to be filled any time soon.
Another significant limitation is that CSRs are only
written for therapeutic, prophylactic or diagnostic
agents, and therefore inadequacies remain in evidence
synthesis of other types of interventions such as surgical
or behavioural interventions.
Individual participant listings
Individual participant listings—which identify partici-
pants by a unique ID—were accessible in 29 of the 78
CSRs we reviewed. But these data are difficult to analyse
because they are presented as database printouts rather
than in the original computer data files. This is under-
standable considering that CSRs are a written/archival
format, but because EMA does not accept SAS format
data files,35 36 the industry standard, third-party access to
databases of patient-level data remains elusive. We see
no compelling reason why all regulators should not
request these from sponsors and make them publicly
available. Whether availability of individual listings
and CRFs, with its attendant laborious analysis, would
increase our understanding of the trial and its results is
unclear. But there is at least one case where the reanaly-
sis of CRFs added invaluable knowledge to that already
available in CSRs.37
The public–private debate
One manufacturer has claimed that the non-release of
case report forms is motivated by concerns over protect-
ing participants’ confidentiality.38 Nothing we have seen
so far corroborates this claim, however an ongoing EMA
working group is specifically discussing issues related to
protecting participants’ confidentiality. Based on current
document releases and position statements, however, it
appears that EMA has deemed case report forms and
individual patient listings to be, in principle, releasable
in their entirety (after a preliminary review).39
Furthermore, individual patient listings are intended to
duplicate information contained in filled case report
forms. The release of case report forms would ensure
the accuracy of individual patient listings with little add-
itional risk to patient confidentiality. Moreover, extra
checks such as registration of protocols by bona fide
research groups could deter any inappropriate use. We
also believe that the sheer bulk of the forms act as a
deterrent against malice.
Size matters
Our range of compression factors shows the scale of
selection and synthesis which must (consciously or
unconsciously) occur in the process of transforming
CSRs into journal-length articles. We found a strong
resemblance in detail, page length, structure and
purpose between the short synopsis section of CSRs and
reports of trials as published in scientific journals. In
some cases essential items of information such as the
trial protocol and its subsequent amendments are simply
not included in journal articles or are replaced by
methods written post facto. In other cases of items essen-
tial for the interpretations of the trial results (such as
the statistical analysis plan), tens of pages are reduced to
a paragraph on sample size calculation in the journal
report, underscoring the lack of detail (and its attendant
problems) common to public forms of trial reporting.
For example, the ratio of words in the protocol of the
CSR for aripiprazole CN138135 to the methods section
for published journal article of the same trial is 30.5
(53 713 words in the CSR protocol vs 1763 words in the
journal article). For the oseltamivir WP16263 trial, the
ratio was 22.7 (26 761 words in the CSR protocol and
amendments vs 1177 words in the journal article).
This compression of information also occurs in databases
not restricted by length, such as ClinicalTrials.gov.40
Our study raises the question of why the medical com-
munity has accepted the low (summary, aggregate) level
of detail found in most peer-reviewed journal publica-
tions compared with the depth of detail available in
CSRs. European regulators recently noted: ‘documents
that provide critical information on a study, such as the
protocol (16.1.1), statistical methods (16.1.9), list of
investigators and study sites and sample case report
forms, would always be needed by reviewers assessing a
study.’41 Why have those outside of the regulatory world
tolerated journal publications lacking such details?
One possibility may be that while the clinical trial
enterprise has changed dramatically in the last half
century, the scientific journal publication model has not.
Since the 1950s, there have been considerable transfor-
mations in the political economy of clinical trials driven
by the increasingly commercialised and global nature of
the pharmaceutical industry, the rise in academic-
industry ‘partnerships’ in medicine and increased com-
munication among regulators. It is now common to find
trials with study centres scattered around the globe. This
increasing complexity and the need to provide an audit
record is reflected in the comprehensive tomes docu-
menting the trials—CSRs—but trial reporting in scien-
tific journals remains limited to summary and aggregate
details. It should be noted, however, that many journals
now have websites which enable them to make available
extended content beyond what traditionally appears in
the printed journal.
Authorship or contributorship?
Examination of CSRs revealed scores of important tech-
nical contributions to the design, conduct and reporting
of each trial. These included contributions from data-
base programmers, records officers and CSR writers,
often invisible in the published journal article. In some
cases, we found no mention in CSRs of individuals
who figured as authors of subsequent published trial
reports while individuals named as CSR authors went
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unacknowledged in journal publications. Current
International Committee of Medical Journal Editors
(ICMJE) guidelines on authorship and contributorship
are largely focused on ensuring those placed on by-lines
deserve to be authors. But the guidelines also suggest
that ‘all contributors who do not meet the criteria for
authorship should be listed in an acknowledgements
section’.42 Given the complexity of clinical trials, the
ICMJE should call for itemised contributorship: the
names of all contributors to be specified along with
their role in the design, conduct, analysis or reporting
of the trial. If the contribution to the trial of most
people goes unrecorded, so does their individual
responsibility for what is produced. Itemised contribu-
torship records, to all phases of a trial, could be piloted
in trial registers.
E3 guidance
The E3 guideline set an excellent standard, but it needs
formal updating and further development. For example,
there should be a self-standing set of definitions for
terms such as ‘CRFs’ and ‘other CRFs submitted’ (section
16.3.2) and a description of how a particular trial fits
within a sponsor’s trial programme of pharmaceutical
development. Apparently forgotten items such as certifi-
cates of analysis (describing the appearance and content
of the interventions being tested) and post-1995 details
such as trial registration numbers should be mentioned.
We hope our review has given CSRs what they have
lacked so far: visibility. CSRs represent a largely
untapped source of detailed data that we believe can
serve as a means of addressing the ravages of reporting
bias in all its forms, leading to a more accurate under-
standing of the effects of medicines.
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